Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. - Wikidata - awgldk - TriplyDB

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

http://www.wikidata.org/entity/Q40732795

about

Maintenance chemotherapy for ovarian cancer Maintenance bioimmunotherapy for epithelial ovarian cancer Optimal primary surgical treatment for advanced epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer - a review of the literature from a developing country perspective Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Current treatment for ovarian cancer.Current status of maintenance therapy for advanced ovarian cancer.Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.Investigational agents for epithelial ovarian cancer.Dose-dense chemotherapy improves mechanisms of antitumor immune response.Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic The Role of Intraperitoneal Carboplatin as Consalidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review.Abagovomab for ovarian cancer.Recent advances in drug delivery strategies for treatment of ovarian cancer.Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Maintenance chemotherapy in the management of epithelial ovarian cancer.Optimal chemotherapy of ovarian cancer with an old regimen.The evidence for increasing cytotoxic dose intensity in the treatment of advanced ovarian cancer.Ovarian carcinomatosis in a dog managed with surgery and intraperitoneal, systemic, and intrapleural chemotherapy utilizing indwelling pleural access ports.Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.

P2860

Q24201758-F76231D7-4A32-4CAB-96A2-C34AFC90AFA1 Q24234761-2ABFFAEB-3A9C-4A48-B63F-C2CAE448573C Q24234923-4D4E02D7-8D86-402C-BBA5-62D8BED7AB78 Q24235427-CC1F15B5-F24E-49AC-830D-E56C622A9F4D Q24791449-2D8EE022-E934-4C9B-9B2E-23DDBD45621E Q28078880-9A747335-76CD-48C4-975A-0A227FD325DE Q34121226-3573AD02-27BB-4840-9FDD-F944576914AE Q34240764-3B442BF3-E5EF-4114-A356-9594CF5FBB2E Q34271924-24B28E9C-3568-4B3C-8616-E69301189212 Q36230572-506F2A37-E47A-4692-9BC7-A556F84948FA Q36284514-95231854-F6B2-4E12-B0C0-505AECDB5D93 Q36511042-9C87EB90-DD5B-4946-BF96-D6C23D9CEB77 Q37347571-EF8F9E86-4B2A-41AE-A06C-7A4C9181A302 Q37608072-AABC3FAF-1F8C-432A-9C20-BD7ADE8CCCD0 Q37829443-875D0125-A9D3-4E81-9D67-28E94227D751 Q37997512-1930AA8A-A967-45DF-973D-428C50492A59 Q38222277-E28E1DFA-6616-415C-8E74-6664BF1ABD22 Q38310412-79B728E3-D746-45BC-B973-76909C0A97BA Q40520307-29D56684-1AC5-4DE1-B3A0-D276150812BB Q40643516-351C6558-1037-4019-AAE1-D71ABF461D79 Q43119082-B74FEAC4-19A9-4127-B241-D5C42238E582 Q44879936-1B472C5B-11CF-4EE1-9843-8E4EA0302356 Q47803030-88408448-EF43-41D7-B78D-126DFD7DFF21 Q50271703-891E972C-130D-45B5-B1B5-AA4B3BF7E6B4

P2860

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

http://www.wikidata.org/entity/Q40732795

description

1992 nî lūn-bûn

@nan

1992年の論文

@ja

1992年学术文章

@wuu

1992年学术文章

@zh-cn

1992年学术文章

@zh-hans

1992年学术文章

@zh-my

1992年学术文章

@zh-sg

1992年學術文章

@yue

1992年學術文章

@zh

1992年學術文章

@zh-hant

name

Randomized prospective trial o ...... in advanced ovarian carcinoma.

@en

type

label

Randomized prospective trial o ...... in advanced ovarian carcinoma.

@en

prefLabel

Randomized prospective trial o ...... in advanced ovarian carcinoma.

@en

P1433

Q40732795-74C02AD9-6B0D-4B88-93A5-97DA1A0CEDAE

P1476

Q40732795-AEA6A427-5A15-4563-B253-F17A17D36FE6

P2093

Q40732795-067CB8A5-2C42-4406-9EF4-CBDA100D8852

Q40732795-306D71BE-AAE7-4FD5-9214-A55BC51798D9

Q40732795-A05C7E83-B027-4F41-A596-D5625FA4ED39

Q40732795-A532CFE5-1FD4-41D7-B936-E7C7D4E4A16A

Q40732795-CD033AAE-DA37-49B2-B5C2-19F1D9BEFCC1

Q40732795-D520E408-C22C-4A3A-B226-7C091158F61E

Q40732795-D65C04B3-3E7C-4C12-97B9-983425272ED5

Q40732795-F1B81C4F-2700-4FB0-8F5B-B5CD720E464F

Q40732795-F484994A-4141-4ADA-8406-29AEB309C9FD

P304

Q40732795-76FC4EE3-8A34-4EC7-89D2-A2B5ADD5E419

P31

Q40732795-96DECEC2-7537-4570-B3A1-C406883CCF9C

P356

Q40732795-1F135184-F63E-417C-AB94-24C25ED9C2E3

P407

Q40732795-07002844-07E9-495B-9D63-1571658D6D47

P433

Q40732795-5DA4FCCE-FFAB-44B1-BBDB-C22B35E3244E

P478

Q40732795-D97B16EA-81C9-4F49-9DCE-5761D415A9CB

P577

Q40732795-CDD5B25A-77F4-44B3-A3FC-DB48386ACB6D

P698

Q40732795-9245AE5A-6808-4FFE-BEB8-4E7639F6C77C

P356

0090-8258(92)90305-3

P1433

Gynecologic Oncology

P1476

Randomized prospective trial o ...... in advanced ovarian carcinoma.

@en

P2093

Almadrones L

http://www.w3.org/2001/XMLSchema#string

Chalas E

http://www.w3.org/2001/XMLSchema#string

Chapman D

http://www.w3.org/2001/XMLSchema#string

Hakes TB

http://www.w3.org/2001/XMLSchema#string

Hoskins WJ

http://www.w3.org/2001/XMLSchema#string

Jones WB

http://www.w3.org/2001/XMLSchema#string

Lewis JL Jr

http://www.w3.org/2001/XMLSchema#string

Markman M

http://www.w3.org/2001/XMLSchema#string

Rubin SC

http://www.w3.org/2001/XMLSchema#string

P304

284-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/0090-8258(92)90305-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

1992-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1612505

http://www.w3.org/2001/XMLSchema#string